{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Incontinence%2C+Urinary+and+Urinary+Bladder%2C+Overactive&page=4",
    "query": {
      "condition": "Incontinence, Urinary and Urinary Bladder, Overactive",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 171,
    "total_pages": 18,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Incontinence%2C+Urinary+and+Urinary+Bladder%2C+Overactive&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Incontinence%2C+Urinary+and+Urinary+Bladder%2C+Overactive&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T23:03:29.302Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03755089",
      "title": "Oral vs Intravesical Analgesia for Office Bladder Botox Injections",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Overactive Bladder Syndrome",
        "Urge Incontinence",
        "Urinary Incontinence",
        "Detrusor Hyperreflexia",
        "Detrusor Instability"
      ],
      "interventions": [
        {
          "name": "Phenazopyridine",
          "type": "DRUG"
        },
        {
          "name": "Lidocaine 2% Injectable Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Women and Infants Hospital of Rhode Island",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 99 Years · Female only"
      },
      "enrollment_count": 110,
      "start_date": "2018-11-01",
      "completion_date": "2021-03-01",
      "has_results": false,
      "last_update_posted_date": "2020-05-29",
      "last_synced_at": "2026-10-06T23:03:29.302Z",
      "location_count": 1,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03755089"
    },
    {
      "nct_id": "NCT01908829",
      "title": "A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Urinary Bladder Diseases",
        "Urinary Bladder Overactive",
        "Urologic Diseases"
      ],
      "interventions": [
        {
          "name": "mirabegron 25 mg",
          "type": "DRUG"
        },
        {
          "name": "mirabegron 50 mg",
          "type": "DRUG"
        },
        {
          "name": "solifenacin 5 mg",
          "type": "DRUG"
        },
        {
          "name": "solifenacin 10 mg",
          "type": "DRUG"
        },
        {
          "name": "mirabegron 25 mg matching placebo",
          "type": "DRUG"
        },
        {
          "name": "mirabegron 50 mg matching placebo",
          "type": "DRUG"
        },
        {
          "name": "solifenacin 5 mg matching placebo",
          "type": "DRUG"
        },
        {
          "name": "solifenacin 10 mg matching placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Europe Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2174,
      "start_date": "2013-07-10",
      "completion_date": "2014-11-25",
      "has_results": true,
      "last_update_posted_date": "2024-10-31",
      "last_synced_at": "2026-10-06T23:03:29.302Z",
      "location_count": 36,
      "location_summary": "Tucson, Arizona • Buena Park, California • Los Angeles, California + 31 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Buena Park",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Valley Village",
          "state": "California"
        },
        {
          "city": "Brooksville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01908829"
    },
    {
      "nct_id": "NCT05880862",
      "title": "Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Urinary Bladder, Overactive",
        "Urinary Incontinence",
        "Accidental Falls"
      ],
      "interventions": [
        {
          "name": "Pelvic Floor Muscle Training",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Mirabegron",
          "type": "DRUG"
        },
        {
          "name": "Trospium Chloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG"
      ],
      "sponsor": "The University of Texas Medical Branch, Galveston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "99 Years",
        "sex": "FEMALE",
        "summary": "60 Years to 99 Years · Female only"
      },
      "enrollment_count": 48,
      "start_date": "2023-09-28",
      "completion_date": "2025-12-27",
      "has_results": false,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-10-06T23:03:29.302Z",
      "location_count": 1,
      "location_summary": "Galveston, Texas",
      "locations": [
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05880862"
    },
    {
      "nct_id": "NCT06483217",
      "title": "Optimal Injection Interval for Intra-Detrusor Botulinum Toxin",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Overactive Bladder",
        "Urinary Urgency",
        "Urinary Incontinence",
        "Urge Urinary Incontinence"
      ],
      "interventions": [
        {
          "name": "Patient-directed follow up",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Louisiana State University Health Sciences Center in New Orleans",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 100,
      "start_date": "2024-07",
      "completion_date": "2025-10",
      "has_results": false,
      "last_update_posted_date": "2024-07-17",
      "last_synced_at": "2026-10-06T23:03:29.302Z",
      "location_count": 1,
      "location_summary": "New Orleans, Louisiana",
      "locations": [
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06483217"
    },
    {
      "nct_id": "NCT00910520",
      "title": "Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Overactive Bladder"
      ],
      "interventions": [
        {
          "name": "onabotulinumtoxinA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 548,
      "start_date": "2009-09",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2013-03-05",
      "last_synced_at": "2026-10-06T23:03:29.302Z",
      "location_count": 1,
      "location_summary": "Laguna Hills, California",
      "locations": [
        {
          "city": "Laguna Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00910520"
    },
    {
      "nct_id": "NCT02045862",
      "title": "A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Urinary Bladder Overactive",
        "Overactive Bladder",
        "Urgency Incontinence",
        "Urinary Bladder Diseases\\Urologic Diseases"
      ],
      "interventions": [
        {
          "name": "Solifenacin succinate",
          "type": "DRUG"
        },
        {
          "name": "Mirabegron",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match solifenacin",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match mirabegron",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Europe B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1829,
      "start_date": "2014-03-17",
      "completion_date": "2016-09-08",
      "has_results": true,
      "last_update_posted_date": "2024-10-31",
      "last_synced_at": "2026-10-06T23:03:29.302Z",
      "location_count": 75,
      "location_summary": "Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 61 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02045862"
    },
    {
      "nct_id": "NCT00323635",
      "title": "A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Urinary Incontinence"
      ],
      "interventions": [
        {
          "name": "tolterodine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "45 Years to 65 Years · Female only"
      },
      "enrollment_count": 19,
      "start_date": "2006-04",
      "completion_date": "2011-01",
      "has_results": true,
      "last_update_posted_date": "2018-03-29",
      "last_synced_at": "2026-10-06T23:03:29.302Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00323635"
    },
    {
      "nct_id": "NCT05543382",
      "title": "Cycling Study With the Axonics System",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Overactive Bladder Syndrome",
        "Urinary Urge Incontinence",
        "Sacral Neuromodulation"
      ],
      "interventions": [
        {
          "name": "Axonics System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Axonics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2022-08-09",
      "completion_date": "2024-12-29",
      "has_results": false,
      "last_update_posted_date": "2025-04-02",
      "last_synced_at": "2026-10-06T23:03:29.302Z",
      "location_count": 6,
      "location_summary": "Naples, Florida • New Orleans, Louisiana • Cleveland, Ohio + 3 more",
      "locations": [
        {
          "city": "Naples",
          "state": "Florida"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Tulsa",
          "state": "Oklahoma"
        },
        {
          "city": "Newton",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05543382"
    },
    {
      "nct_id": "NCT00147654",
      "title": "Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Urinary Incontinence"
      ],
      "interventions": [
        {
          "name": "Tolterodine ER 4 mg QD",
          "type": "DRUG"
        },
        {
          "name": "Tamsulosin 0.4 mg QD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "40 Years and older · Male only"
      },
      "enrollment_count": 830,
      "start_date": "2004-11",
      "completion_date": "2006-05",
      "has_results": false,
      "last_update_posted_date": "2021-01-27",
      "last_synced_at": "2026-10-06T23:03:29.302Z",
      "location_count": 95,
      "location_summary": "Birmingham, Alabama • Homewood, Alabama • Tucson, Arizona + 92 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Culver City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00147654"
    },
    {
      "nct_id": "NCT00688688",
      "title": "Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Urinary Bladder, Overactive"
      ],
      "interventions": [
        {
          "name": "Mirabegron",
          "type": "DRUG"
        },
        {
          "name": "Tolterodine",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Mirabegron",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Tolterodine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2792,
      "start_date": "2008-04-25",
      "completion_date": "2010-05-06",
      "has_results": true,
      "last_update_posted_date": "2024-11-20",
      "last_synced_at": "2026-10-06T23:03:29.302Z",
      "location_count": 106,
      "location_summary": "Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 96 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00688688"
    }
  ]
}